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1Primary systemic vasculitides are an uncommon group of diseases characterized by relapsing and remitting immune-
mediated inflammation of blood vessels. They affect patients of 
all ages and pose unique diagnostic and therapeutic challenges. 
Systemic vasculitis can be broadly defined by the size of the af-
fected vessels into small vessel vasculitis (SVV), medium vessel 
vasculitis (MVV), and large vessel vasculitis (LVV) with some 
overlap.1 In LVV, the inflammatory response begins at the ad-
ventitia and spreads inward toward medial and intimal layers.2 
This results in the development of occlusive and aneurysmal 
vascular lesions. In contrast, small vessel inflammation typi-
cally begins with endothelial injury and intimal inflammation, 
which propagates outward to the media and adventitia.3 Further 
spread to the adventitia results in a panarteritis, although this is 
more typical of MVV, which shares features of both.4 The early 
inflammatory injury of the intima with subsequent activation 
of the coagulation cascade in small caliber vessels explains the 
thrombotic and necrotizing pathology that characterizes SVV.
Please see www.ahajournals.org/atvb/atvb-focus 
for all articles published in this series.
Although effective, current treatments for systemic vas-
culitis are associated with significant morbidity,5 and survival 
remains poor with many patients experiencing chronic re-
lapsing systemic inflammation that contributes to the devel-
opment and progression of cardiovascular disease.6,7 Indeed, 
≈15% of patients experience a major adverse cardiovascular 
event within 5 years of diagnosis.6,7 Identifying vasculitis early, 
assessing response to therapy, and detecting disease relapse re-
main important clinical challenges. The last decade has seen 
major advances in our understanding of the pathogenesis of 
vasculitis. These discoveries have led to the development of 
novel treatments, which seek to provide greater efficacy and a 
more acceptable side effect profile. In this review, we discuss 
the recent advances in understanding disease mechanisms of 
the major vasculitides in adults, the consequent development of 
new treatments, and how existing and novel imaging techniques 
may be used to improve diagnosis and disease monitoring.
Large Vessel Vasculitis
Clinical Context and Challenges
LVV is the most common primary systemic vasculitis8,9 and 
includes giant cell arteritis (GCA) and Takayasu arteritis (TA). 
The central feature of both is granulomatous arteritis that 
involves the aorta and its major branches.2 GCA exclusively 
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affects individuals aged >50 years with a female-to-male pre-
dominance of 3:1. Additionally, GCA is more common in 
patients of North European descent with an incidence of 20 
to 30 per 100 000 people but is uncommon in Asian ethnic 
groups, incidence ≈1.5 per 100 000.10,11 It typically affects the 
branches of carotid, vertebral, and temporal arteries resulting 
in the classical symptoms of headache, jaw claudication, and 
loss of vision.1 Large vessel GCA involvement is increasingly 
recognized in ≤70% to 80% of patients with GCA and is asso-
ciated with an increased mortality risk related, in part, to an-
eurysm formation and dissection.12 In contrast, TA primarily 
affects females <50 years of age, has a worldwide incidence 
of ≈0.8 per million, and is rare in North Europe but is more 
common in South East Asia.11,13,14 TA typically involves the 
aorta and its primary branches leading to vascular occlusion 
with claudication, aneurysm formation, aortic insufficiency, 
and cardiac failure.1
LVV is a chronic, relapsing disease with ≈80% of patients 
with GCA15 and ≈50% of patients with TA16 experiencing a re-
lapse within 5 years of diagnosis. Current treatment is heavily 
reliant on prolonged use of glucocorticoids, which is asso-
ciated with infections, osteoporotic fractures, hypertension, 
weight gain, and diabetes mellitus.17 The limited success of 
steroid-sparing agents such as methotrexate18 and azathio-
prine19 in clinical trials of GCA has reinforced this depend-
ence. In contrast to SVV, LVV lacks validated markers of 
disease activity to guide immunosuppression and detect sub-
clinical progressive disease. This chronic, relapsing low-grade 
systemic inflammation contributes to the development of car-
diovascular disease, which is a major source of morbidity and 
mortality.6,20,21
Novel Mechanisms, Novel Treatments
Targeting Leucocyte-Cytokine Signatures in LVV
Vascular inflammation in LVV is characterized by 2 dis-
tinct leucocyte-cytokine signatures (Figure 1). The IL (in-
terleukin)-6/Th17 cell/IL-17 signature is a key mediator of 
the early inflammatory response within the vessel wall and 
is glucocorticoid sensitive. A separate IL-12/Th1 cell/IFN-γ 
(interferon-γ) pathway promotes sustained granulomatous in-
flammation and vascular smooth muscle cell (VSMC) prolif-
eration and appears glucocorticoid resistant in GCA.22
These concepts are supported by clinical studies show-
ing elevated circulating IL-6, IL-12, and IL-1723 during 
active GCA alongside increased Th17/IL-17 and Th1/IFNγ 
expression in culprit lesions on temporal artery biopsy.24,25 
Following glucocorticoid treatment, circulating IL-6 and 
IL-17, as well as vessel Th17/IL-17 expression, fall mirroring 
clinical improvement.20 However, circulating IL-12 concen-
trations and tissue Th1/IFNγ expression remain unchanged.24 
Relative tissue expression of these leucocyte-cytokine signa-
tures may influence outcomes as greater culprit lesion expres-
sion of IL-17 has been shown to predict an earlier response to 
glucocorticoids, likelihood of glucocorticoid discontinuation, 
and a lower risk of relapse.25 Extrapolating these concepts to 
TA should be done with caution as recent data show that, de-
spite similar cytokine signatures, glucocorticoids had little 
effect on IL-17 but suppressed IFNγ.26 Reasons for this are 
unclear but may be because of differences in typical affected 
age group, ethnicity, and genetic associations between TA 
and GCA.
Targeting IL-6
IL-6 is a potent mediator of the inflammatory response in both 
the vessel wall and the systemic circulation. Tocilizumab is 
a humanized monoclonal antibody that competitively inhib-
its IL-6 by binding to circulating and membrane-bound 
IL-6 receptors. The first study of tocilizumab in GCA was 
published in 2016. This single-center, randomized, placebo-
controlled double-blind study enrolled 30 patients, most with 
new-onset GCA.27 Patients received monthly tocilizumab or 
placebo alongside tapered glucocorticoids. The primary out-
come of complete remission by 12 weeks was achieved by 
17 (85%) patients in the tocilizumab arm compared with 4 
(40%) patients in the placebo arm. Tocilizumab was also as-
sociated with a greater relapse-free survival at 1 year, longer 
Nonstandard Abbreviations and Acronyms
ADA2  adenosine deaminase 2
ANCA  antineutrophil cytoplasmic antibody
BAFF  B-cell activating factor
BlyS  B-lymphocyte stimulator
C5aR  C5a receptor
CRP  C-reactive protein
CT  computed tomography
CTA  computed tomographic angiography
EGPA  eosinophilic granulomatosis with polyangiitis
ET-1  endothelin-1
ETA  endothelin-A
ETB  endothelin-B
Ga-DOTATATE  gallium-68-labeled [1,4,7,10-tetraazacyclododecane-
N,N′,N″,N‴-tetraacetic acid]-D-Phe1, Tyr3-octreotate
GCA  giant cell arteritis
GiACTA  giant cell arteritis actemra
GLUT  glucose transporter
GPA  granulomatosis with polyangiitis
IFN-γ  interferon-γ
IL  interleukin
LVV  large vessel vasculitis
MPO  myeloperoxidase
MR  magnetic resonance
MRA  magnetic resonance angiography
MVV  medium vessel vasculitis
PAN  polyarteritis nodosa
PD-1  programmed death-1
PD-L1  programmed death ligand-1
PET  positron emission tomography
PR3  proteinase-3
SST-2  somatostatin receptor subtype 2
SVV  small vessel vasculitis
TA  Takayasu’s arteritis
TNFα  tumor necrosis factor-α
TSPO  translocator protein
VSMC  vascular smooth muscle cell
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time to first relapse and lower cumulative glucocorticoid dose. 
Adverse advents were similar between arms.
These findings were extended by the phase 3 GiACTA trial 
(Giant Cell Arteritis Actemra) that enrolled 251 patients with 
new-onset, relapsing, or refractory GCA.28 Randomization 
was to one of tocilizumab weekly plus 26-week glucocorti-
coid taper, tocilizumab every 2 weeks plus 26-week gluco-
corticoid taper, placebo plus 26-week glucocorticoid taper, or 
placebo plus 52-week glucocorticoid taper. The primary out-
come of sustained remission at 52 weeks was met by >50% of 
patients in the tocilizumab arms demonstrating superiority to 
placebo (≈15%).28 Tocilizumab was also associated with lower 
rates of disease flares, longer time to flare, and a lower cumu-
lative glucocorticoid dose. There was no difference in total 
adverse events across the 4 groups, and the highest number 
of serious adverse events occurred in the slow glucocorticoid 
taper group.29
The compelling evidence from these trials led to the 
approval of tocilizumab for GCA by the Food and Drug 
Administration in the United States last year and the National 
Institute for Health and Care Excellence in the United 
Kingdom this year. The optimal duration of treatment is un-
clear. This is important given the costs of tocilizumab are 
≈$18 000 (≈£12 000) per patient-year. Importantly, from a 
therapeutic perspective, ≈50% of patients receiving tocili-
zumab in GiACTA failed to achieve sustained remission at 1 
year suggesting that targeting IL-6 alone might be insufficient 
for adequate disease control in some patients.28
A key effect of IL-6 production is the induction of 
CRP (C-reactive protein) transcription, which drives the 
Figure 1. Targeting key mechanisms in the pathogenesis of large vessel vasculitis (LVV). Cross-sectional diagram of a large vessel depicting important path-
ogenic pathways of vasculitis. Upper left shows vessel structure in health; upper right shows the IL (interleukin)-6/Th17 cell/IL-17 pathway; lower right 
shows IL-12/Th1 cell/IFNγ (interferon-γ) pathway; lower left shows the ET-1 (endothelin-1) system. Adventitial dendritic cells are activated by an as yet 
unknown trigger, leading to monocyte, CD4+, and CD8+ T-cell infiltration via the vasa vasorum. Cellular infiltration stimulates the release of several proinflam-
matory cytokines including IL-6 and IL-12. IL-6 induces CD4+ T-cell differentiation toward a Th17 phenotype. These Th17 cells secrete IL-17, which in turn 
recruits monocytes and neutrophils to the inflamed medial layer. The ensuing florid inflammatory response spreads from the adventitia toward the intima 
with giant cell formation. Glucocorticoids can effectively suppress this pathway, but more precise targeting of IL-6 is possible by the monoclonal antibody 
tocilizumab. In parallel, IL-12 promotes polarization of CD4+ to a Th1-IFNγ secreting phenotype. IFNγ release orchestrates macrophage recruitment and gran-
uloma formation, as well as triggering pathways that lead to proliferation and inward migration of vascular smooth muscle cells (VSMCs). This pathway is 
resistant to suppression by glucocorticoids but can be inhibited by ustekinumab. The widespread uncontrolled T-cell activation can be targeted by abatacept, 
which blocks T-cell interaction with antigen presenting cells. The inflammatory milieu within the vessel wall causes upregulation of ET-1 at the protein level 
and increased VSMC ET receptor expression. ET-1 promotes VSMC proliferation and migration that in combination with the effects of IFNγ results in intimal 
hyperplasia and luminal stenosis characteristic of LVV. In vitro data suggest this may be ameliorated by ET receptor antagonism.
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systemic inflammatory response and associated symptoms.30 
Consequently, tocilizumab’s inhibition of IL-6 leads to a rapid 
suppression of circulating CRP, which results in significant 
symptomatic improvement. This renders CRP ineffective as a 
marker of disease activity and has raised concerns that tocili-
zumab may mask ongoing inflammation at the level of the ves-
sel wall. These concerns are supported by clinical trial data. 
In the GiACTA trial, one patient developed arteritic ischemic 
optic neuropathy while receiving tocilizumab,28 and a recent 
imaging substudy of the first tocilizumab trial by Villiger et 
al27 reported that one-third of patients in tocilizumab arm 
(n=3) had persisting or increased mural contrast enhancement 
on magnetic resonance angiography (MRA) despite clinical 
remission.31 Larger studies particularly with concurrent serial 
multimodal imaging may help clarify these concerns.
In TA, the first randomized, double-blind, placebo-
controlled trial of tocilizumab was published in late 2017.32 
Thirty-six patients aged >12 years with relapsing TA received 
high-dose glucocorticoids to induce remission before random-
ization to either tocilizumab or placebo given weekly along-
side a tapering glucocorticoid dose. Intention-to-treat analysis 
failed to demonstrate a clear difference in primary outcomes 
of time to relapse (P=0.056). The per-protocol analysis did 
suggest a longer time to relapse in patients receiving tocili-
zumab (P=0.03) with no increased risk of infections or other 
serious adverse effects. Further studies are needed to define 
the role of IL-6 inhibition in TA.
Targeting IL-12 and IL-23
IL-12 and IL-23 induce the polarization of T cells toward 
INFγ secreting Th1 cells and IL-17 secreting Th17 cells, 
respectively (Figure 1).22 IL-12 and IL-23 share a P40 sub-
unit that can be targeted by the novel monoclonal antibody, 
ustekinumab. Ustekinumab is licensed for use in psoriasis, 
psoriatic arthritis, and Crohn colitis,33,34 and data in LVV are 
emerging. A recent open-label trial recruited 25 patients with 
refractory GCA and administered ustekinumab at baseline, 1 
month, and then 3 months for up to a year.35 Ustekinumab 
allowed significant reductions in glucocorticoid dose from a 
median of 20 to 5 mg, and ≈25% of patients were able to stop 
glucocorticoids completely within the 12 months after enroll-
ment. Interestingly, in patients who underwent computed to-
mographic (CT) angiography (CTA) before and after (n=8), 
all showed an improvement in mural thickness with complete 
resolution seen in 4 patients.35 Whether these radiological 
changes occur because of specific inhibition of Th1/INFγ-
mediated VSMC proliferation by ustekinumab or simply 
by reducing vessel inflammation overall needs clarification. 
Further randomized trials are now awaited.
Targeting T-Cell Activation
Uncontrolled T-cell activation is a central feature of the in-
flammatory response in LVV. Abatacept is a fusion protein 
that inhibits the interaction between CD28 on T cells and 
CD80 or CD86 on antigen-presenting cells and thus pre-
vents T-cell activation.36 The clinical benefit of targeting this 
pathway has recently been assessed by 2 separate randomized 
controlled trials, one in GCA37 and the other in TA,38 with con-
trasting results. Both trials had a similar design in which all 
enrolled patients received abatacept over 8 weeks to induce 
disease remission. Those who achieved remission at 12 weeks 
after enrollment were randomized 1:1 to either monthly abata-
cept or placebo. All patients received tapering glucocorticoids 
from entry, and the primary end point was relapse-free sur-
vival at 12 months.37,38
In the GCA trial, 41 of 49 (83%) enrolled patients were ran-
domized (ie, achieved remission with abatacept), and relapse-
free survival was 48% with abatacept as maintenance therapy 
compared with 31% with placebo (P=0.049).37 Patients in 
the abatacept arm spent ≈10 months in remission compared 
with ≈4 months with placebo, and there were no differences 
in infection rates or prednisolone exposure before relapse.37 
However, in the TA trial, the first ever RCT in TA, fewer 
patients were randomized (26 of 34; 74%), and no difference 
in relapse-free survival at 12 months was seen between abata-
cept and placebo (22% versus 40%, respectively).38 These 
data provide further support that GCA and TA are distinct, as 
suggested by their differential geoepidemiology, cytokine pro-
files, and TA-specific genetic associations.39 It is worth noting 
that in the GCA trial ≈50% of patients randomized were new 
presentations spread equally between treatment arms.37 In the 
TA trial, all patients randomized to abatacept had relapsing 
disease and median disease duration of >5 years compared 
with <1 year in the placebo arm.38 Thus, this group likely had 
difficult-to-control disease and was prone to relapse, which 
may have influenced achievement of the primary outcome. 
Regardless, these trials indicate a potential role for abatacept 
in LVV that warrants additional study.
Imaging of LVV
The diagnosis of GCA often involves tissue biopsy, and per-
forming an interval biopsy to assess disease activity is not 
feasible. In large vessel GCA and TA, obtaining tissue for di-
agnosis is frequently impossible. Commonly used circulating 
measures of disease activity such as CRP and erythrocyte 
sedimentation rate normalize rapidly after commencement of 
treatment,40 despite ongoing inflammation at the level of the 
vessel41 and can remain within normal limits even when di-
sease relapses.42 Furthermore LVV lacks a validated marker 
of disease activity such as the Birmingham Vasculitis Activity 
Score in antineutrophil cytoplasmic antibody (ANCA)–
associated vasculitis. The potential to visualize and track large 
vessel inflammation using imaging, therefore, represents an 
exciting breakthrough in LVV and may yield critical biomark-
ers of disease activity to guide treatment. In recognition of this, 
the European League Against Rheumatism released guidance 
for clinicians on the use of imaging in LVV including technical 
and operational parameters for ultrasound, CT, magnetic res-
onance imaging, and positron emission tomography (PET).43 
This guidance also details an extensive future research agenda 
demonstrating a clear intent to harness the power of multi-
modal imaging to improve patient outcomes. Table 1 summa-
rizes the current modalities utilized in imaging LVV.
Structural Imaging
Ultrasound
Color doppler ultrasound of the temporal arteries in sus-
pected cranial GCA is a safe, rapidly available, cost-effective 
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technique for diagnosis and is recommended as the primary 
imaging modality of choice by European League Against 
Rheumatism.43 Detection of homogenous hypoechoic mural 
thickening, the halo sign, has a reported pooled sensitivity 
and specificity of 77% and 96%, respectively, which rises 
to 100% specificity if present bilaterally or persists despite 
luminal compression.43 However, a recent multicenter study 
of 381 patients with suspected GCA reported a much lower 
sensitivity of 54% with ultrasound, but this still compared 
favorably to that of temporal artery biopsy (39%).45 The use 
of sonographers with less experience may have contributed 
to the observed lower sensitivity of ultrasound and highlights 
its operator-dependent limitations. Although ultrasound can-
not reliably assess aortic involvement in LVV, it can identify 
axillary and femoral vasculitis.46,47 Assessment of the axillary 
arteries is particularly useful for diagnosis as they are not 
commonly affected by atherosclerosis compared with lower 
limb vessels, which can affect the utility of femoral vessel 
assessment.48 The role of ultrasound in disease monitoring is 
unclear as time to regression of the halo sign after starting 
treatment is highly variable and halo signs around larger ves-
sels may persist for months to years.48
CT Angiography
CTA provides a structural assessment of extracranial and 
aortic vessels. It can report the extent of LVV and delineate 
mural thickening, luminal stenosis (Figure 2), and aneurysmal 
dilation, as well as mural contrast enhancement (assumed to 
represent active vasculitis).44 Thus, CTA may be able to mon-
itor development of vascular complications in patients with 
LVV, such as aortic aneurysms. Prospective data supporting 
the role of CTA for diagnosis of LVV are few but show ev-
idence of large vessel involvement in ≈70% of patients with 
biopsy-proven, active GCA.49,50 Data on tracking disease ac-
tivity with CTA are equally scarce but have reported persistent 
mural thickening on follow-up imaging in two-thirds of patients 
with biopsy-proven GCA despite clinical and biochemical re-
mission.51 However, nearly all patients had resolution of mural 
contrast enhancement on repeat CTA,51 suggesting that cur-
rent CTA-derived metrics may be too coarse to reliably track 
disease. The high effective radiation dose of CTA limits its 
use in young patients and for serial imaging, but evidence sup-
porting the safety of low-dose CT protocols may change this.52 
This is important in practical terms as CT is more widely ac-
cessible than magnetic resonance (MR). Regardless, the use of 
iodinated contrast carries the risks of allergic reactions as well 
as contrast-related kidney dysfunction.
MR With or Without Angiography
MR with or without angiography provides superior soft tis-
sue contrast compared with CTA, avoids exposure to ionizing 
radiation (Figure 3), and is the recommended modality for 
diagnosis of suspected TA given the younger age of affected 
patients.43 High-resolution MR of cranial vessels has a similar 
sensitivity and specificity to ultrasound for the diagnosis of 
cranial GCA and thus is recommended if ultrasound is incon-
clusive or unavailable.43 After contrast administration, mural 
enhancement on T1-weighted images is suggestive of active 
vessel inflammation. Suppression of signals from both adi-
pose tissue (by fat saturation or short T1 inversion recovery 
sequences) and blood flow (black-blood sequences) enhances 
visualization of mural contrast uptake particularly in the ca-
rotid, subclavian, and axillary arteries, which lie close to 
subcutaneous and fascial fat. T2-weighted images can demon-
strate mural edema indicative of vasculitis but are considered 
by European League Against Rheumatism to be less sensitive 
Table 1. Multimodal Imaging of Large Vessel Vasculitis
Modality
Diagnostic 
Role Sensitivity Specificity Key Imaging Features
Disease 
Activity Role Strengths Weaknesses
US + 77% 96% Halo sign ± Accessible; cost-effective Operator dependent; 
unable to detect 
aortic disease
Cranial MRI + 73%–93% 81%–88% Mural thickening; contrast 
enhancement
ND Operator independent Expensive; unable 
to detect LV-GCA; 
patients with MR-
incompatible devices
CTA + GCA, 73%*; 
TA, 100%*
GCA, 78%*; TA, 
100%*
Stenosis; aneurysm 
dilation; mural 
thickening±enhancement
± Assess burden; detect 
complications
Radiation exposure; 
iodinated contrast 
load
MRA + GCA, ND; TA, 
100%*
GCA, ND; TA, 
100%*
Stenosis; aneurysmal 
dilation; mural 
thickening±enhancement
± Assess burden; detect 
complications; no radiation 
exposure; integrated cardiac 
images
Less accessible; 
expensive
PET + GCA, 
76%–90%; TA, 
70%–87%
GCA, 89%–98%; 
TA, 73%–84%
Increased mural tracer 
uptake
± Assess burden and activity; 
combined with CT/MR 
for hybrid structural and 
functional imaging
Radiation exposure; 
current tracers lack 
specificity
Sensitivity and specificity values are pooled from available studies reviewed in references.43,44 CT indicates computed tomography; CTA, computed tomography 
angiography; GCA, giant cell arteritis; LV-GCA, large vessel giant cell arteritis; MR, magnetic resonance; MRA, magnetic resonance angiography; MRI, magnetic 
resonance imaging; ND, no data; PET, positron emission tomography; TA, Takayasu arteritis; and US, ultrasound.
*Data derived from a single study.
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and prone to artifact.43 MRA can also assess the wider vas-
culature to define disease extent and is, therefore, attractive 
for the longitudinal monitoring of vessel structure. A recent 
study of both patients with GCA and TA at various stages 
of their disease found that MRA provided better evaluation 
of disease extent compared with PET but correlated poorly 
with clinical and circulating measures of disease activity.53 
Glucocorticoids and biologic therapy can modify mural 
edema and enhancement on MRA,54 but the heterogenous 
nature of the study population in terms of age, disease type, 
and duration may explain the observed discordance between 
imaging and clinical assessment.53 A further strength of MR 
imaging is that specific cardiac sequences can be readily in-
tegrated alongside vascular imaging, which is particularly rel-
evant for TA. This approach has been shown to be feasible55 
and can provide assessments of left ventricular volume, ejec-
tion fraction, aortic root dilation, and myocardial scarring 
alongside standard assessments of vasculitis disease activity 
and burden.55 Such data may identify patients at high risk of 
poor outcomes who might benefit from targeted intervention, 
but this requires evaluation in large studies. Limitations of MR 
include its availability, cost, and patient tolerability, particu-
larly if multiple vessel beds are imaged. Lack of availability 
may limit its use in GCA where rapid diagnosis and therapy 
are essential to avoid irreversible visual loss.
An important limitation of both CTA and MRA is a lack 
of standardized imaging-based outcome measures for di-
sease burden and activity. Both European League Against 
Rheumatism and the Outcome Measures Rheumatology 
groups have highlighted the urgent need for such measures for 
use in clinical trials.43,57 A recent study designed a cross-plat-
form angiographic scoring system applicable to both CTA and 
MRA images.58 This was then validated in a cross-sectional 
and longitudinal study of 131 patients (96 with TA, 35 with 
GCA), and scoring correlated well with disease burden at 
baseline, subsequent disease activity, and progression of vas-
cular lesions.58 External validation in larger prospective stud-
ies is required to examine the utility of this system further.
Molecular Imaging
Positron Emission Tomography
Both CTA and MRA provide detailed structural assessments 
of vessel inflammation, but treatment decisions are prima-
rily influenced by disease activity—a functional metric. 
PET is a highly sensitive molecular imaging technique that 
employs radiotracers to measure the activity of metabolic 
Figure 2. Computed tomography (CT) angiography in large vessel vascu-
litis (LVV). Coronal oblique multiplanar reconstruction contrast-enhanced 
CT with angiography demonstrating diffuse mural thickening of the tho-
racic and abdominal aorta (Ao; red asterisks) in a patient with LVV. AoR 
indicates aortic root; LA, left atrium; PA, pulmonary artery; and RV, right 
ventricle.
Figure 3.  18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)–magnetic resonance (MR) in large vessel vasculitis. A, Cardiac MR image 
with black-blood sequence in the sagittal plane demonstrating circumferential mural thickening of AoR (aortic root) and ascending Ao (aorta; red asterisks). B, 
Same MR sequence fused with 18F-FDG PET showing diffuse homogenous FDG uptake along the length of ascending Ao in keeping with severe active vas-
culitis. LA indicates left atrium; and PA, pulmonary artery. Adapted from Tarkin et al56 with permission. Copyright © 2016, the Authors.
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processes in vivo. 18F-fluorodeoxyglucose (18F-FDG) is a glu-
cose analogue that contains an 18-fluoride group in place of 
a hydroxyl group. After uptake into cells by GLUT (glucose 
transporter) proteins, 18F-FDG undergoes phosphorylation by 
hexokinase; however, the 18-fluoride group prevents entry 
into downstream metabolic pathways. Reconversion of phos-
phorylated 18F-FDG by glucose-6-phosphatase is slow, and 
the end product is unable to exit the cell because of its nega-
tive charge.59 Consequently, 18F-FDG is trapped intracellularly 
undergoing emission decay that is detected by scintigraphy. 
Thus, 18F-FDG reports cellular glucose utilization as a marker 
of cellular metabolic activity.59
Cells with high glycolytic activity show greater 18F-FDG 
uptake because of greater GLUT expression.59 Macrophages, 
monocytes, and lymphocytes have all been shown to upregu-
late GLUT-1, GLUT-3, and GLUT-5 expression in response 
to inflammatory stimuli, represented by avid 18F-FDG uptake 
in inflamed tissues.60–62 18F-FDG PET has been widely used 
to study atherosclerotic inflammation where the intensity of 
tracer uptake reflects plaque macrophage burden.63 These 
properties provide a biological rationale for 18F-FDG PET im-
aging in vasculitis.63 PET involves around 50% of the effec-
tive radiation of a diagnostic CT but is often combined with 
low-dose attenuation correction CT or MR to provide precise 
anatomic localization of tracer uptake (Figure 4).43
PET in LVV
18F-FDG is the most widely studied PET radiotracer with pro-
spective data supporting its utility in the diagnosis of LVV.64–69 
A recent meta-analysis of predominantly prospective studies 
totaling 170 patients reported a pooled sensitivity of 76% and 
specificity of 93% of 18F-FDG PET for diagnosing LVV.70
There are few data with respect to tracking disease activity 
longitudinally. Blockmans et al71 studied 35 patients with GCA 
who had a temporal artery biopsy followed by a baseline 18F-
FDG PET before treatment and then the scan was repeated at 
3 and 6 months. 18F-FDG uptake fell significantly at 3 months 
compared with baseline, but ongoing vessel uptake persisted 
in >50% of patients at 6 months despite clinical and biochem-
ical remission.71 Grayson et al72 recruited 56 patients with LVV 
(30 GCA, 26 TA) and 59 comparator subjects (35 with hyper-
lipidemia, thus more likely to have aortic atherosclerosis; 17 
LVV mimics and 9 healthy controls). Thirty-five patients with 
LVV had a follow-up PET scan with a mean interval of ≈6 
months. Qualitative 18F-FDG uptake was significantly greater 
in patients with LVV compared with comparator subjects 
and in active disease compared with remission. In addition, 
greater global 18F-FDG uptake while in clinical remission was 
predictive of future relapse.72 Importantly, 17% of patients in 
the comparator group had 18F-FDG uptake qualitatively inter-
preted as active vasculitis, highlighting the limitations of this 
tracer as specific marker of disease activity in LVV. Similar 
limitations have been encountered in TA where patients with 
prosthetic vascular grafts demonstrated increased 18F-FDG 
uptake in grafts on PET-CT despite clinical or biochemical 
remission and no evidence of graft infection.73 Follow-up PET 
imaging (n=9) ≈15 months later showed no change in graft 
18F-FDG uptake despite the use of additional immunosuppres-
sion in the intervening period.73
The available data show discordance between imaging-
reported vessel inflammation and clinical markers of disease 
activity. Whether persisting 18F-FDG uptake or mural thick-
ness represents subclinical vasculitis, remodeling, or ather-
osclerosis is unclear and is a critical area for further study. 
Addressing this issue will require hybrid imaging modalities, 
better delineation of mural tracer uptake patterns, greater met-
abolic specificity of tracers, and clearly defined clinical end 
points. The advent of hybrid PET-MR for LVV29 with its supe-
rior soft tissue contrast and lower radiation exposure for serial 
imaging may be the likeliest platform to help achieve this, but 
the limited available data are conflicting.29,74 The diagnostic 
sensitivity of 18F-FDG PET for active GCA appears preserved 
Figure 4. Assessing disease activity in large vessel vasculitis (LVV) with positron emission tomography (PET). A, Sagittal attenuated corrected 18F-fluorode-
oxyglucose (18F-FDG) PET (left) and fused 18F-FDG PET-computed tomography (CT; right) images from a patient with active LVV before treatment. Images 
show diffuse increased FDG uptake in relation to the aortic wall (black and white arrows) corresponding to the mural thickening demonstrated on the CT in 
Figure 3. B, Repeat 18F-FDG PET-CT images obtained after 6 mo of treatment with glucocorticoids and successful clinical remission demonstrates resolution 
of the abnormal mural aortic FDG uptake.
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for ≤3 days after commencing glucocorticoids65 but falls sig-
nificantly by 10 days,75 highlighting the particular challenge 
of accessibility to novel imaging modalities when prompt 
treatment is essential.
Medium Vessel Vasculitis
Clinical Context and Challenges
Polyarteritis nodosa (PAN) is the predominant MVV in 
adults. Kawasaki disease—the other major form of MVV 
and an acute arteritis of childhood—is discussed elsewhere.76 
PAN is uncommon with an estimated incidence of 1 to 10 
per million.77 Both sexes are affected equally, and the peak 
age range of onset is between 40 and 60 years.78 The etio-
pathogenesis of PAN is strongly linked to viral hepatitis in-
fection, particularly hepatitis B virus,79 which compromised 
over one-third of 348 PAN cases in the largest case series to 
date.78 The incidence of hepatitis B virus–related PAN has 
declined substantially over the last 4 decades after improve-
ments in immunization, transfusion practice, and hepatitis B 
virus therapy.78,80
PAN can manifest as a systemic vasculitis or a skin-limited 
form, cutaneous PAN. Both are characterized by a transmural 
necrotizing arteritis of muscular arteries. The most commonly 
affected sites are the skin (causing livedo reticularis and ul-
ceration) and peripheral nerves (leading to a mononeuritis 
multiplex).4 Involvement of visceral vessels is also common 
with multiple irregular arterial stenoses and microaneurysms 
demonstrable (Figure 5) on contrast angiography in ≤90% of 
patients81,82 These can occur in any organ but are the most fre-
quent in the renal and mesenteric arteries; however, reliable 
frequency data are limited by sampling bias.78 Renal involve-
ment can lead to segmental renal infarction and impaired renal 
function, as well as hypertension, whereas mesenteric disease 
manifests as gut ischemia, perforation, and hemorrhage from 
aneurysm rupture.78 Despite treatment, mortality may be as 
high as 35% at 5 years in those with severe disease as indi-
cated by the Factor Five Score.78,83
Novel Mechanisms and Potential Treatments
Pathogenesis of PAN
Compared with other vasculitides, the pathogenesis of PAN 
is poorly understood. Endothelial injury, through immune 
complex deposition and viral replication, has been proposed 
as a key trigger in hepatitis B virus–related PAN.84 This is 
supported by the success of antiviral therapy and plasma ex-
change in achieving sustained remission but does not explain 
the residual majority of PAN, which is noninfection related. 
In these cases, long-term immunosuppression with gluco-
corticoids alongside other agents such as cyclophosphamide, 
methotrexate, or azathioprine improves patient outcomes 
and supports an autoimmune component to pathogenesis.85 
However, relapse rates can reach 50% at 2 years, and these 
drugs have significant side effects.78
T-Cell Activation and ADA2 in PAN
Recent studies exploring immunopathogenesis have found 
higher IFN-γ expression in CD4+ T cells in patients with PAN 
compared with patients with granulomatosis with polyangiitis 
(GPA) but noticeably lower IL-17 expression.86 IFN-γ is a 
potent inhibitor of regulatory T-cell function, and this same 
study found significant impairment in the immunosuppressive 
potential of regulatory T cells isolated from patients with PAN 
compared with those isolated from healthy controls.86 The rel-
ative lack of IL-17 expression seen in this study may partly ex-
plain the absence of granulomata in PAN, compared with LVV 
where IL-17 (from Th17 cells) and IFN-γ (from Th1 cells) 
synergistically lead to granuloma formation.22 Blocking T-cell 
activation in PAN using TNFα (tumor necrosis factor-α) 
blockers or TCZ has shown some promise in limited case 
series.87–89
The identification of a potential genetic basis for PAN 
has provided novel perspective into pathogenesis and 
renewed interest in the potential role of TNFα blockade. 
Whole-exosome and candidate gene sequencing of patients 
with familial PAN and PAN-like syndromes and unaffected 
family members has identified several novel loss-of-function 
homozygous or compound heterozygous mutations of genes 
encoding ADA2 (adenosine deaminase 2), formerly known 
as cat eye syndrome CECR1 gene.90,91 The predominant 
site of ADA2 expression is in myeloid cells, which export 
ADA2 into the extracellular compartment.92 In vitro data 
have shown that ADA2 drives monocyte differentiation and 
proliferation of macrophages and CD4+ T cells92 and that 
ADA2 knockout skews monocyte polarization toward an 
inflammatory M1 phenotype with subsequent disruption of 
endothelial layer integrity.90 Thus, deficiency of ADA2 may 
initiate a vicious cycle of inflammation and vascular disrup-
tion that manifests as a systemic medium vasculopathy with 
the clinical and histopathologic features of PAN. Indeed, 
many patients with deficiency of ADA2 syndromes fit the 
diagnostic criteria for PAN.
The vasculopathy associated with loss of ADA2 typically 
presents in childhood, but adult presentations have also been 
reported.90,91,93,94 Across various series, these patients show 
variable responses to standard treatments for PAN. In the larg-
est European study, glucocorticoids while initially effective 
were associated with relapse on tapering.94 Other treatments 
such as cyclophosphamide, methotrexate, and azathioprine 
were ineffective at controlling disease during steroid taper.94 
However, in both European94 and ultrasound91 series, TNFα 
blockade has shown consistent efficacy in suppressing vas-
culitis, although what constitutes response was not clearly 
or uniformly defined. This efficacy extended to patients with 
life-threatening disease despite maximal tolerated doses of 
cyclophosphamide.91
Why TNFα blockade is particularly effective in defi-
ciency of ADA2 vasculopathy is unclear. Skin biopsies from 
these patients show a necrotizing, nongranulomatous MVV 
with abundant staining for TNFα,90 but further work is needed 
to clarify the precise mechanisms. The relevance of ADA2 
to all forms of PAN is also unclear. ADA2 activity appears 
important in the immune response to infections, particu-
larly intracellular pathogens.95 It is possible that more subtle 
impairments of ADA2 could be induced or exacerbated by 
intracellular infection thereby promoting immune dysregu-
lation and vascular injury. Assessing ADA2 gene expression 
in all patients presenting with PAN is potentially feasible 
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given its low incidence and may reveal a novel pathway of 
pathogenesis.
Imaging in PAN
Structural and Molecular Imaging
Microaneurysms or arterial stenoses are present in a majority 
of patients with PAN at presentation.78,81,82 Fluoroscopic-
guided contrast angiography is considered the optimal mo-
dality for identifying these abnormalities with a reported 
sensitivity and specificity of ≈90%.96 However, this carries 
the risks associated with arterial cannulation including bleed-
ing, embolization, and pseudoaneurysm formation in addition 
to risks of contrast administration such as allergic reactions 
and renal dysfunction. CTA and MRA provide a noninvasive 
assessment of but may be less sensitive for the detection of 
microaneurysms (typically 1 to 5 mm in size).97 Although 18F-
FDG PET has been used in small studies of PAN, showing 
increased uptake in medium arteries,98 its use has not been 
adequately assessed.
Similar to LVV, assessment of disease activity is challeng-
ing in PAN. The vast majority of imaging data in PAN relate 
to diagnosis with fluoroscopic contrast angiography. Data for 
CTA and MRA are limited to individual case reports and case 
series with CTA and MRA. However, interval imaging across 
all 3 modalities shows resolution of microaneurysms with di-
sease remission99,100 (Figure 5) and progression of lesions with 
refractory disease,101 thus may provide useful additional infor-
mation on top of standard clinical and biochemical parameters. 
The lack of ionizing radiation makes MRA an attractive mo-
dality for future longitudinal studies to track disease activity. 
Hybrid PET/MR imaging may enable more refined tracking 
Figure 5. Computed tomography angiography (CTA) in polyarteritis nodosa. A, Coronal maximum intensity projection CTA demonstrating bilateral intrarenal 
microaneurysms (white arrows) and a large right subcapsular perinephric hematoma (red arrow). B, Repeat CTA 6 mo later following immunosuppressive 
treatment and achievement of clinical remission shows resolution of radiological changes.
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of disease activity particularly in patients with visceral vessel 
lesions that are at high risk of catastrophic complications.
Small Vessel Vasculitis
Clinical Context and Challenges
ANCA-associated vasculitis is the commonest systemic SVV 
in adults and has an incidence of 20 to 30 per million pop-
ulation.102 It is characterized by necrotizing inflammation of 
small arteries, arterioles, and capillaries, usually in the pres-
ence of autoantibodies directed against the neutrophil cy-
toplasmic granular proteins PR3 (proteinase-3) and MPO 
(myeloperoxidase),1 although ≈10% patients with the charac-
teristic clinical and histological features of ANCA-associated 
vasculitis lack measurable circulating ANCA.103 The peak 
age of onset of ANCA-associated vasculitis is in the fifth and 
sixth decade with no clear sex predominance.102 There are 3 
clinical subtypes, GPA, microscopic polyangiitis, and eosin-
ophilic GPA (EGPA); the key features of these are described 
in Table 2. From a clinical perspective, it is noteworthy that 
significant overlap between clinical subtypes exists.1 More re-
cently, focus has shifted to classification by ANCA subtype 
after the discovery of genetically distinct origins for MPO and 
PR3 ANCA.104 These differences may underpin the recog-
nized differences in clinical expression of disease105 and have 
future implications for treatment. Overall, however, the risk of 
premature mortality is >2.5× greater than in an age- and sex-
matched general population.106
Fifty percent of patients with ANCA-associated vascu-
litis experience a relapse within 5 years of diagnosis.109 PR3+ 
disease is frequently associated with granulomatous inflam-
mation, as well as higher rates of relapse and refractory di-
sease.105 The reasons for this are unknown but may relate to 
their differing genetic basis of ANCA subtypes.104 In addition, 
granulomata may act as tertiary lymphoid organs110 and harbor 
autoreactive B cells facilitating their escape from autodeletion 
or depletion by cytotoxic treatments. As with LVV, persisting 
low-grade inflammation contributes to the development of 
cardiovascular disease morbidity and mortality.7 Treatment of 
ANCA-associated vasculitis is divided into distinct induction 
and maintenance phases.111 The goal of induction therapy is 
rapid, effective suppression of the immune response to limit 
inflammatory organ injury. Maintenance therapy provides 
lower intensity immunosuppression over the medium to long 
term to prevent disease relapse and accrual of organ damage. 
In both phases, achieving effective immunosuppression while 
minimizing toxic side effects is challenging.112 Agents such as 
cyclophosphamide and rituximab are effective but similarly 
associated with an increased risk of infection and cancer.112 
Finally, the lack of reliable tools for assessing disease activity 
while on treatment and stratifying the risk of future relapse are 
critical challenges. This makes it difficult not only to identify 
patients with ongoing disease activity who require treatment 
escalation but also patients who are at low risk of relapse who 
can safely stop potentially toxic immunosuppression.
Novel Mechanisms and Treatments
B Cells in ANCA-Associated Vasculitis
The introduction of the alkylating agent cyclophosphamide 4 
decades ago transformed the short-term prognosis of ANCA-
associated vasculitis.113,114 Cyclophosphamide efficacy is at-
tributable to depletion of all major leucocyte subsets,115 but 
a marked suppressive effect on circulating lymphocytes, 
particularly B cells, was noted in several early studies.115–117 
Subsequent histological evidence of activated B cells in 
granulomata from patients with GPA,118 the role of B cells in 
antibody-mediated autoimmunity, and strong evidence for the 
pathogenicity of ANCA,104,119 all support an important role for 
B cells in the pathogenesis of ANCA-associated vasculitis and 
provide a rationale for targeted B-cell depletion (Figure 6). 
Furthermore, the side effects of cyclophosphamide, including 
an increased risk of malignancy, infection, and infertility,112 
are a leading factor in the search for selective B-cell targeting.
B-Cell Depletion
The chimeric monoclonal antibody rituximab selectively 
depletes CD20 expressing B cells, and its development rep-
resents the most important therapeutic advance in ANCA-
associated vasculitis since cyclophosphamide. The RAVE120 
and RITUXVAS121 trials established noninferiority of ritux-
imab to cyclophosphamide for remission induction of 
ANCA-associated vasculitis including for those with organ 
and life-threatening presentations. At 18 to 24 months of fol-
low-up, rituximab induction with no additional maintenance 
therapy continued to demonstrate noninferiority to cyclophos-
phamide induction with azathioprine maintenance in relation 
to rate of relapse, end-stage renal disease, and death.122,123 
Importantly, the cumulative dose of glucocorticoids was no 
different between the 2 groups.122,123
Sustained B-cell depletion with a suppressed ANCA 
was associated with the lowest risk of relapse in RAVE and 
RITUXVAS.122,123 However, B-cell return occurred as early 
as 6 months after rituximab, and most patients had B-cell 
repopulation by 18 months post-dose.43 The MAINRITSAN 
trial explored whether, after cyclophosphamide induction, 
Table 2. Clinical and Biochemical Features of ANCA-Associated Vasculitis 
Subtypes8,107,108
Features GPA MPA EGPA
Incidence, per million 
per y
5–10 6–8 1–3
ANCA present, % ≈50%–90% ≈90% ≈40%
 Predominant subtype PR3 MPO MPO
ENT involvement +++ + ++
Lung involvement ++ ++ +++
Pulmonary hemorrhage + ++ −
Kidney involvement ++ +++ +
Nerve involvement + ++ +++
Unique features Orbital disease; 
airway stenosis
Interstitial 
lung 
changes
Eosinophilia; 
cardiac disease; 
adult-onset 
asthma
ANCA indicates antibody to neutrophil cytoplasmic antigens; EGPA, 
eosinophilic granulomatosis with polyangiitis; ENT, ear, nose, and throat; 
GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, 
myeloperoxidase; and PR3, proteinase-3.
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rituximab administered every 6 months for 18 months would 
offer greater protection against relapse versus standard-of-
care azathioprine. Major relapse rates were significantly lower 
in the rituximab group (5% versus 29%; P=0.002).124 The ben-
efits of rituximab extended for ≤5 years after enrollment and 
were associated with a modest improvement in survival.125 
However, tailoring maintenance treatment with rituximab 
according to the B-cell count or ANCA titer does not appear 
to be any better (or worse) than fixed-interval dosing in terms 
of efficacy and safety.126
What Next for B-Cell Depleting Therapy?
The optimal dosing interval for rituximab remains unclear. 
The RITAZAREM trial is in progress and explores whether 
higher dose rituximab (1000 mg) given more frequently (every 
4 months for 5 doses) after rituximab induction for relapsing 
ANCA-associated vasculitis will provide greater protection 
compared with azathioprine.127 RAVE and RITUXVAS did 
not include patients with EGPA; so it is unclear whether the 
benefits of B-cell depletion translate to this unique subtype of 
ANCA-associated vasculitis. However retrospective data sug-
gest potential benefit of rituximab particularly in EGPA as-
sociated with circulating ANCA.128 The ongoing REOVAS129 
and MAINRITSEG130 trials will shed light on the utility of this 
approach for induction and maintenance therapy in EGPA, 
respectively.
Although recommended for remission induction and 
maintenance therapy in ANCA-associated vasculitis,111 the 
available data do not support rituximab as being safer than 
other immunosuppressive agents. In clinical trials, the fre-
quency of infections following rituximab was similar to cy-
clophosphamide, but this may be driven by concomitant 
glucocorticoid.122,123 Reactivation of latent hepatitis B infec-
tion,131 persisting hypogammaglobulinemia,132 and late-onset 
neutropenia133 are important side effects encountered with 
rituximab that contribute to morbidity. Furthermore, the chi-
meric structure of rituximab is immunogenic and has been 
linked to the development of infusion reactions and antichi-
meric antibodies that can limit its efficacy.134 The development 
Figure 6. Targeting key mechanisms in the pathogenesis of antibody to neutrophil cytoplasmic antigens (ANCA) vasculitis. Cross-sectional diagram of a small 
artery depicting important pathogenic pathways of ANCA vasculitis. Upper left shows vessel structure in health; upper right shows the B-cell pathways; 
lower right shows the alternative complement pathway; lower left shows IL (interleukin)-5 in eosinophilic granulomatosis with polyangiitis (EGPA). B-cell in-
volvement in antibody production, T-cell costimulation, and B-cell activation contribute to production and binding of circulating ANCA to primed neutrophils 
expressing cytoplasmic antigens PR3 (proteinase-3; red circles) and MPO (myeloperoxidase; blue circles). ANCA binding triggers neutrophil degranulation 
with subsequent endothelial injury. Depleting B cells by with rituximab, blocking costimulation with abatacept and inhibiting B-cell activation factors like BAFF 
(B-cell activating factor) with belimumab offers sophisticated inhibition of these pathways. Binding of complement protein C5a to its surface receptor on 
neutrophils leads to translocation of PR3 and MPO to the surface (neutrophil priming). Subsequent binding of circulating ANCA results in endothelial injury. 
Avacopan inhibits C5a binding. IL-5 promotes proliferation and migration of eosinophils out of bone marrow into the circulation. The precise steps that trigger 
subsequent eosinophil-mediated vascular injury are unclear but may involve ANCA. Targeting of IL-5 in EGPA is now possible using the monoclonal antibody 
mepolizumab. C5aR indicates C5a receptor; and MAC, membrane attack complex.
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of fully humanized anti-CD20 antibodies such as ofatumumab 
and obinutuzumab will hopefully address these issues.
However, the absence of consistent evidence showing an 
increased risk of cancer following B-cell depletion is a po-
tential benefit of this treatment option.135 Recent data from a 
single tertiary center reported a 3- and 4-fold increased risk 
of cancer (mainly nonmelanomatous skin cancer) with cy-
clophosphamide compared with the general population and 
patients receiving rituximab, respectively.136 Interestingly, the 
apparent protective effects of rituximab against risk of ma-
lignancy showed a dose-dependent relationship136—a concept 
supported by experimental data.137
B-Cell and T-Cell Costimulation and Depletion
The presence of granulomatous T-cell infiltrates in lung138 and 
renal biopsies139 along with impaired regulatory T-cell func-
tion in blood samples from patients with ANCA-associated 
vasculitis glomerulonephritis suggests a pathogenic role of 
T cells (Figure 6).140 Recent attention has focused on block-
ing T-cell costimulation by activated, antigen-presenting B 
cells with abatacept. In an open-label trial of 20 patients with 
a nonorgan threatening relapse of GPA, abatacept led to di-
sease remission in 80% and steroid discontinuation in ≈75% 
with a safety profile comparable to other treatment options.141 
An option for managing nonsevere relapse that permits ste-
roid minimization would be of major clinical value in ANCA-
associated vasculitis. The ongoing multicenter, randomized 
placebo-controlled ABROGATE trial should define to what 
extent abatacept can achieve this.142
Depletion of both B and T cells can be achieved using alem-
tuzumab—a monoclonal antibody with specificity for CD52. 
CD52 is also expressed, in lower abundance, on monocytes/
macrophages and eosinophils143; thus alemtuzumab exerts 
effects on a range of cellular components involved in the path-
ogenesis of ANCA-associated vasculitis. Retrospective data 
suggest a role for alemtuzumab as induction therapy for se-
vere/refractory ANCA-associated vasculitis but also reported 
high rates of infection and malignancy following its use.144 An 
open-label phase IV trial is in progress.145
B-Cell Survival and Relapse: Targeting BAFF
B-cell maturation is influenced by several cytokines in-
cluding BAFF (B-cell activating factor; also known as BlyS 
[B-lymphocyte stimulator]) and is increasingly recognized as 
important in the pathogenesis of relapsing ANCA-associated 
vasculitis. BAFF signaling regulates the transition of naive 
B cells into memory B cells and mature plasma cells.146 
Increased BAFF expression is evident in patients with active 
vasculitis,147 and preclinical data suggest that high BAFF con-
centrations can promote the survival of autoreactive B cells 
that under normal conditions would be deleted.148 These auto-
reactive B cells can escape to peripheral lymphoid follicles 
where they may be less effectively depleted by anti-CD20 
therapies.110 In addition, B-cell depletion appears to increase 
concentrations of BAFF.149 Thus, B-cell depleting therapies 
in the context of high levels of BAFF may promote survival 
of autoreactive B cells that are able to trigger relapse during 
B-cell repopulation.
Belimumab is a fully humanized monoclonal antibody 
that prevents circulating BAFF binding to BAFF receptors on 
B cells (Figure 6). In trials of patients with systemic lupus er-
ythematosus, this approach was effective in reducing relapse 
and glucocorticoid requirements.150 In ANCA-associated vas-
culitis, the BREVAS study attempted to compare belimumab 
to azathioprine for maintenance of remission in GPA and mi-
croscopic polyangiitis. However, the trial was stopped early 
because of suboptimal recruitment with no concrete evidence 
of improved benefit. Combining BAFF targeting with other 
anti–B-cell therapies may offer additional benefit by prevent-
ing autoreactive B-cell escape and enabling more complete 
B-cell depletion.
Alternative Complement Pathway: 
Targeting C5a Receptors
The complement system is a central mediator of antibody-
mediated immune responses.151 C5 is a potent effector pro-
tein in this pathway, exerting its effects through its cleavage 
products C5a, a powerful chemoattractant, and C5b, part 
of the membrane attack complex that lyses target cells.152 
Activation of the alternative complement pathway is evident 
in ANCA-associated vasculitis. Kidney biopsies from patients 
with ANCA-associated glomerulonephritis show deposi-
tion of alternative pathway components in active glomerular 
lesions.153 In addition, high circulating levels of C3, C5a, and 
soluble C5b-9 (membrane attack complex) have been found 
in patients with active vasculitis, which subsequently fall 
in disease remission.154 In vitro, C5a primes neutrophils for 
ANCA-induced degranulation that leads to endothelial injury 
(Figure 6).155 Finally, in murine MPO models, knocking out 
C5a and C5aR (C5a receptor) is protective against the devel-
opment of necrotizing glomerulonephritis, as is pharmacolog-
ical blockade of C5aR.156,157
Clinical trial evidence of the utility of the C5a receptor 
inhibition with avacopan has recently emerged.158 Sixty-
seven patients with ANCA-associated vasculitis were ran-
domized to either high-dose glucocorticoids, avacopan plus 
low-dose glucocorticoids, or avacopan alone alongside cy-
clophosphamide or rituximab induction. The primary end 
point of treatment response at 12 weeks (a 50% reduction 
from baseline in the Birmingham Vasculitis Activity Score) 
occurred in 86% of the avacopan/glucocorticoid and 81% 
of the avacopan-alone groups, compared with 70% in the 
glucocorticoid group (P=0.002 and P=0.01, respectively). 
Markers of renal injury and inflammation fell across 
all groups, but reductions occurred earlier and were of a 
greater magnitude with avacopan. Serious adverse effects 
such as psychiatric disturbances and new-onset diabetes 
mellitus were more common in the high-dose glucocor-
ticoid group.158 These promising results suggest that glu-
cocorticoid-free remission induction in ANCA-associated 
vasculitis is achievable with novel targeted therapies. The 
ongoing larger and of longer duration phase 3 ADVOCATE 
trial will explore this further.159
Eosinophils in EGPA: Targeting IL-5
The immunopathology of EGPA is unique: it often lacks cir-
culating ANCA, and the role of B cells and associated cyto-
kines such as BAFF is unclear.160 Indeed, ANCA-negative 
EGPA and ANCA-positive EGPA (predominantly because 
of circulating MPO ANCA) are increasingly recognized as 
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separate diseases with distinct genetic associations and clin-
ical features.161 ANCA-negative EGPA has associations with 
single-nucleotide polymorphisms within the IL-10 promoter 
gene,162 whereas ANCA-positive forms are frequently associ-
ated with HLA-DRB1 and 7.163 These genetics may explain, 
in part, the differences in clinical phenotype as cardiac in-
volvement is much more common in ANCA-negative patients 
but renal and nerve involvement are more frequent in those 
with circulating ANCA.164 In addition, a representative animal 
model does not exist, and patients with EGPA are underrep-
resented in the major clinical trials of ANCA vasculitis, thus 
they may not derive the same benefits from treatments with 
proven efficacy for other subtypes. A central feature of EGPA 
is a tissue and blood eosinophilia. IL-5 is a key mediator of 
this and stimulates eosinophil proliferation, survival, and mi-
gration into vessels and tissues (Figure 6).160 Clinical studies 
have found high IL-5 concentrations in bronchoalveolar la-
vage samples of patients with active EGPA, which stimulates 
bronchospasm and bronchial eosinophilic infiltration.165
Mepolizumab is a fully humanized recombinant mono-
clonal antibody with specificity for IL-5. Small, open-label 
studies indicated the potential of mepolizumab to deplete 
circulating eosinophils, induce remission, and allow steroid 
taper in EGPA.166,167 A recent randomized, double-blinded trial 
assigned 136 patients with refractory or relapsing EGPA to 
monthly mepolizumab or placebo.168 After 52 weeks, patients 
in the mepolizumab arm spent significantly more time in re-
mission, with 28% spending >24 weeks in remission com-
pared with 3% in the placebo group.168 Serious adverse events 
were more frequent in the placebo arm, and mepolizumab 
was well tolerated. The relapse rate was high: 47% and 82% 
in the mepolizumab and standard-of-care arms, respectively. 
This may reflect the inclusion of patients with long-standing 
disease and a high tissue eosinophil burden that is resistant 
to IL-5 blockade.168 Long-term treatment with mepolizumab 
may be necessary as relapse occurred rapidly following dis-
continuation. However, mepolizumab is an important advance 
in EGPA and received Food and Drug Administration ap-
proval in late 2017.
Imaging in ANCA-Associated Vasculitis
Despite validated tools such as Birmingham Vasculitis 
Activity Score, assessing disease activity in patients on treat-
ment remains challenging in ANCA-associated vasculitis. 
While interval biopsies to assess disease activity may be more 
feasible compared with GCA, this approach is impractical. 
Thus, a noninvasive means of detecting small vessel inflam-
mation would be equally valuable in SVV.
PET in ANCA-Associated Vasculitis
PET may provide additional information about disease activity 
in patients with lung or sinonasal involvement, typically seen 
in GPA. Standard CT offers coarse structural metrics of di-
sease activity such as a reduction in size of nodules, masses, or 
mucosal thickening but often these do not fully resolve.169 In 
addition, patients with GPA often report symptoms suggestive 
of disease activity170 but lack a robust clinical measure of this. 
There are no prospective studies of the use of 18F-FDG PET 
to monitor disease activity in ANCA-associated vasculitis, but 
retrospective studies have reported increased 18F-FDG uptake 
in clinically affected organs.171 Persistent 18F-FDG uptake on 
follow-up imaging was seen in patients with elevated disease 
activity scores suggesting PET could at least match current 
tools.171 Prospective studies are needed to explore whether this 
imaging modality can identify currently unidentifiable and 
subclinical smoldering disease.
Future Directions
New Indications for Established Drugs
Targeting VSMCs: the Endothelin System in LVV
Suppressing remodeling due to vasculitis may targeting of 
pathways beyond leucocyte-IL signaling. ET-1 (endothelin-1) 
is the most potent endogenous vasoconstrictor in man and is 
largely produced by endothelial cells.172 ET-1 exerts its effects 
through 2 receptors: the ETA (endothelin-A) and the ETB (endo-
thelin-B) receptor.172 Within the vasculature, ETA receptors are 
located on VSMC, whereas ETB receptors are expressed on 
both VSMC and endothelial cells.173 ETA receptor activation 
is generally associated with pathological effects such as vas-
oconstriction, inflammation, and atherosclerosis,173 whereas 
ETB receptors mediate vasodilation and clearance of ET-1, al-
though VSMC ETB receptors do promote vasoconstriction.173 
Temporal artery biopsies from patients with GCA have re-
vealed increased ET-1 peptide, ETA, and ETB, expression in 
arteritic lesions.174,175 Additionally, a study of inflamed vessel 
explants from patients with GCA showed that ET-1 stimulated 
VSMC migration in vitro (Figure 1).175 Furthermore, this out-
growth was inhibited by pretreatment with an ETB antagonist 
and to a lesser extent by an ETA antagonist.175
Pure ETB antagonism is unlikely to be translatable to 
clinical settings given the potential deleterious effects of 
unopposed systemic ETA activation. Ambrisentan, bosen-
tan, and macitentan are dual ETA/B antagonists that are cur-
rently approved for use in pulmonary arterial hypertension.176 
Pulmonary arterial hypertension is characterized by florid 
VSMC proliferation in pulmonary vessels driven by an ac-
tivated ET system, which can be ameliorated by ETA/B an-
tagonism.177 A similar role of ET-1 in vascular remodeling in 
LVV suggests a potential novel therapeutic indication for this 
drug class that is already available in the clinic. There are no 
registered clinical trials of ET receptor antagonism in LVV. 
However, ET antagonism has emerged as an important poten-
tial therapeutic strategy in chronic kidney disease with a re-
cent large clinical trial demonstrating both efficacy and safety 
in slowing the loss of kidney function.178
Structural Imaging
Interrogating the Retinal Microvasculature
The eye acts as a window to the systemic and regional micro-
vasculature. Systemic diseases such as hypertension and 
diabetes mellitus have profound effects on retinal microves-
sels as demonstrated by structural and functional retinal im-
aging.179,180 Retinal optical coherence tomography captures 
the chorioretinal microcirculation, in particular, the highly 
vascularized choroid, with near-histological resolution.181 In 
systemic disease, optical coherence tomography has revealed 
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retinal vessel remodeling and chorioretinal thinning in hy-
pertension, diabetes mellitus, and CKD.182–184 Additionally, 
preclinical and clinical optical coherence tomography have 
linked retinal microvascular pathology to circulating and 
histological markers of injury within the kidney.184 We have 
shown that the highly vascularized choroid thins with increas-
ing levels of systemic inflammation184 potentially indicative 
of microvascular injury. In addition, in patients with ANCA-
associated glomerulonephritis, we found that the severity of 
choroidal thinning mirrored the degree of vascular inflamma-
tion as represented by the number of glomerular crescents and 
focal necrotizing lesions on renal histology.184 Studies to ex-
plore whether metrics are modified by treatment will clarify 
these associations further. The strong association between 
GCA and ischemic ocular complications such as arteritic is-
chemic optic neuropathy and retinal ischemia from choroidal 
hypoperfusion suggests optical coherence tomography may 
offer a novel means of identifying patients at risk of impend-
ing ischemic ocular complications.185
Novel MR/MRA Techniques for LVV
Improving MR imaging specificity for disease activity 
assessment in LVV is an important area for further research. 
Diffusion weighted imaging sequences detect the restriction of 
intracellular proton movement, typically in the context of cy-
totoxic edema following acute ischemia. Diffusion weighted 
imaging sequences are well established in MR imaging of 
acute stroke and highly sensitive for the detection of early 
infarcts. A recent proof-of-concept study hypothesized that 
the intense cellular infiltrate of LVV may also restrict proton 
movement within the vessel wall and thus be detectable using 
diffusion weighted imaging.186 In combination with 18F-FDG 
PET, diffusion weighted imaging was able to differentiate be-
tween overtly active, smoldering, inactive GCA and health.186 
Mural contrast enhancement as shown by conventional gad-
olinium-based contrast agents is assumed to represent active 
vessel inflammation but can also be seen in inactive disease.187 
Newer contrast agents such as gadofosveset trisodium are bet-
ter retained in the intravascular compartment and have shown 
promise in differentiating between active and inactive mural 
inflammation in a small study of TA.188 Both these techniques 
require further study to better define their potential utility.
Molecular Imaging
18F-FDG reliably reports vessel wall macrophage hypermetab-
olism, but this is prominent in atherosclerosis, as well as LVV, 
and discriminating between these pathologies is challeng-
ing.189 The pattern of 18F-FDG uptake in atheromatous disease 
is often focal and related to the intima unlike the linear, dif-
fuse medial uptake in vasculitis.190 Furthermore, in untreated 
LVV, 18F-FDG uptake is intense (described as greater than 
liver uptake when using visual assessment scoring), whereas 
low-grade uptake (less than liver uptake) is suggestive of ath-
erosclerosis.190 Large arterial calcification identified by hybrid 
PET/CT may aid identification of atherosclerosis over LVV.190 
However, the lack of specificity of 18F-FDG limits its use in 
assessing disease activity in patients on treatment where low-
grade subclinical vasculitis and atheroma may coexist. The de-
velopment of PET tracers to identify differential polarization 
of macrophages or immune checkpoint activity may offer a 
more precise means of assessing disease activity, as well as 
differentiating between vasculitic and atherosclerotic forms of 
vascular inflammation.
Imaging Macrophage Activation
Activated macrophages express a range of specific receptors 
that can be targeted by radiotracer ligands. TSPO (translocator 
protein; also known as peripheral benzodiazepine receptor) is 
expressed on mitochondria of phagocytic cells of mononuclear 
lineage. The ligand PK11195 has specificity for TSPO with 
binding confirming the presence of activated macrophages in 
atheromatous carotid endarterectomy specimens.191 PET with 
11C-PK11195 has been used widely in neuroinflammatory di-
sease192 because of increased TSPO expression in microglia, 
but data in LVV are limited. A small study suggested the po-
tential for 11C-PK11195 to track disease activity in LVV, as 
well as differentiate between quiescent and unstable carotid 
atheroma, but no larger studies have followed.193
Gallium-68-labeled [1,4,7,10-tetraazacyclododecane-
N,N′,N″,N‴-tetraacetic acid]-D-Phe1, Tyr3-octreotate 
(Ga-DOTATATE) is a PET tracer with specificity for the 
SST-2 (somatostatin receptor subtype 2) expressed by mac-
rophages.194,195 Recent data have demonstrated markedly 
increased SST-2 expression on activated macrophages with a 
proinflammatory M1 phenotype compared with both unstimu-
lated and anti-inflammatory M2 macrophages.196 In addition, 
Ga-DOTATATE uptake by carotid atheroma in endarterec-
tomy specimens strongly correlated with macrophage burden 
and SST-2 gene expression, while uptake on clinical PET-CT 
reliably identified culprit carotid and coronary lesions.196 
Moreover, Ga-DOTATATE was better than 18F-FDG at iden-
tifying high-risk coronary plaques, and uptake was more dis-
crete allowing precise anatomic description of uptake.196 The 
power of Ga-DOTATATE to reflect macrophage behavior has 
exciting translational potential for LVV. Studies to assess 
SST-2 expression and Ga-DOTATATE uptake in temporal ar-
tery biopsy specimens with tracer uptake on concurrent PET 
imaging before and after immunosuppression are needed to 
fully evaluate its potential in LVV.
Imaging Immune Checkpoints
The PD-1 (programmed death-1)/PD-L1 (programmed death 
ligand-1) system is an immune checkpoint pathway involved 
in the regulation of T-cell responses to antigens.197 Under 
normal conditions, interaction of PD-L1 with PD-1 leads to 
controlled suppression of exuberant T-cell activation by pro-
moting T-cell apoptosis.197 Overactivity of this checkpoint 
leads to impaired T-cell tumor surveillance, and therapeutic 
inhibition of the PD-1/PD-L1 checkpoint has led to improved 
patient outcomes in oncology.198
PD-L1 expression appears divergent in different forms of 
vascular inflammation with downregulation in LVV and over-
expression in atherosclerosis.199 In LVV, this downregulation 
allows unopposed T-cell activation and leads to the classic 
florid inflammatory response.200 In atherosclerosis, sustained 
PD-L1 overexpression appears to impair T-cell activation and 
clonal expansion, which normally have protective roles in 
response to plaque inflammation.201 PET tracers that bind to 
PD-1/PD-L1 and report its activity to guide anticancer therapy 
D
ow
nloaded from
 http://ahajournals.org by on June 24, 2019
Farrah et al  Novel Management of Vasculitis  15
have now been evaluated in clinical studies with encouraging 
results.202,203 With further development, scientists may be able 
to precisely and noninvasively define the nature of vessel in-
flammation and monitor response to treatment through so-
called immuno-PET. Further detailed characterization of these 
pathways, including changes after treatment, is necessary, but 
PD-1/PD-L1 targeting offers an exciting novel imaging and 
therapeutic frontier in vasculitis.
Conclusions
Major advances in the management of systemic vasculitis 
have taken place over the last decade. Advances in pathogen-
esis and imaging technology have translated into safer, more 
effective treatments and less invasive diagnostic and monitor-
ing methods. Despite the success of blocking IL-6 and T-cell 
activation in GCA, relapse rates and glucocorticoid use remain 
high suggesting further refinement is needed. This is partic-
ularly true for TA where these novel agents appear to offer 
little benefit. The discovery of mutations in ADA2 in familial 
PAN syndromes may yield further insights into classical PAN 
and treatment options including TNFα blockade. ANCA-
associated vasculitis has seen landmark improvements in clin-
ical outcomes by targeting B cells. Recent trials of therapies 
that target B-cell activation, complement and IL-5 provide en-
couraging evidence of better outcomes for these patients. In 
addition, imaging has emerged to take a central role in vascu-
litis with ultrasound, CT, MRA, and PET each demonstrating 
unique strengths and limitations for diagnosis of LVV. Robust 
imaging-based methods of assessing disease activity remain 
elusive because of a discordance with clinical biomarkers, 
lack of comparable histology in many cases, and confounding 
by atherosclerosis. The advent of novel tracers and immuno-
PET that allow noninvasive tracking of immune checkpoint 
activity may provide a solution. Further refinement of both 
treatments and imaging technology will hopefully allow cli-
nicians to offer patients with vasculitis noninvasive disease 
monitoring, more precise treatments, and truly individualized 
patient management in the near term.
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• The emergence of novel biologics such as abatacept, tocilizumab, and ustekinumab offers more precise targeting of the immune response in 
large vessel vasculitis and has shown promise in minimizing glucocorticoid reliance.
• Novel therapies for B-cell targeting in antineutrophil cytoplasmic antibody–associated vasculitis aim to build on the success of rituximab. 
Complement blockade has shown promise in preclinical studies and recent clinical trials while mepolizumab demonstrates the key role of 
interleukin-5 in eosinophilic granulomatosis with polyangiitis.
• Multimodal imaging including positron emission tomography with computed tomography and magnetic resonance has proven utility in diag-
nosis of large vessel vasculitis. The role of positron emission tomography in tracking disease activity is highly promising but needs greater 
refinement.
• Immuno-positron emission tomography and retinal optical coherence tomography may be the next generation of imaging modalities to offer 
noninvasive assessment and monitoring of systemic vasculitis.
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